Posted inInternal Medicine Oncology Specialties
Evaluating Methylphenidate for Fatigue Management in Advanced Cancer: Insights from the MePFAC Randomized Controlled Trial
The MePFAC trial demonstrates that methylphenidate is safe but does not significantly reduce fatigue compared to placebo in advanced cancer patients receiving palliative care, challenging previous assumptions about its efficacy.
